Hematology Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hematology Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Chronic Myeloid Leukemia
Researchers from University of Milan, Department of Clinical Medicine publish findings in chronic myeloid leukemia
April 16th, 2007
A report, "Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation," is newly published data in The EMBO Journal. According to a study from Monza, Italy, "Self-renewal of Bcr-Abl(+) chronic myeloid leukemia (CML) cells is sustained by a nuclear activated serine/threonine-(S/T) unphosphorylated beta-catenin. Although beta-catenin can be tyrosine (Y)-phosphorylated, the occurrence and biological relevance of this covalent modification in Bcr-Abl-associated leukemogenesis is unknown." "Here we show that Bcr-Abl levels control the degree of beta-catenin protein stabilization by affecting its Y/S/T-phospho content in CML cells....
Source: Hematology Week (2007-04-16)
|
